Hederacolchiside A1

Hederacolchiside A1
Product Name Hederacolchiside A1
CAS No.: 106577-39-3
Catalog No.: CFN94808
Molecular Formula: C47H76O16
Molecular Weight: 897.10 g/mol
Purity: >=98%
Type of Compound: Triterpenoids
Physical Desc.: Powder
Targets: MEK | ERK | Antifection
Source: The rhizomes of Anemone raddeana Regel
Solvent: DMSO, Pyridine, Methanol, Ethanol, etc.
Price: $118/20mg
Hederacolchiside A1 shows anti-leishmanial activity, it exhibits a strong antiproliferative activity on all stages of development of the parasite by altering membrane integrity and potential. Hederacolchiside A1 shows antiproliferation activities in three cancer cell lines with the IC50 value of 2.4 uM, it exhibits a preferential cytotoxicity on a pigmented melanoma cell line.
Inquire / Order: manager@chemfaces.com
Technical Inquiries: service@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680

Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • Nat Prod Commun.2014, 9(5):679-82
  • Metabolites. 2023, 13(11):1122.
  • Pathogens.2018, 7(3):E62
  • Front Cell Dev Biol.2021, 9:764263.
  • University of Manitoba2023, 37433.
  • Viruses2023, 15(6), 1377
  • Food Funct.2022, 13(23):12105-12120.
  • Universidade Estadual Paulista2017, 42785
  • VNU J of Science: Med.&Pharm. Sci.2023, 39(1):20-29.
  • Research Square2021, March 3rd.
  • Zingibroside R1

    Catalog No: CFN92517
    CAS No: 80930-74-1
    Price: Inquiry(manager@chemfaces.com)
    Prosapogenin CP4

    Catalog No: CFN90391
    CAS No: 75799-18-7
    Price: $490/5mg
    Raddeanin A

    Catalog No: CFN99985
    CAS No: 89412-79-3
    Price: $98/20mg
    Hederacolchiside A1

    Catalog No: CFN94808
    CAS No: 106577-39-3
    Price: $118/20mg
    Ecliptasaponin D

    Catalog No: CFN90619
    CAS No: 206756-04-9
    Price: $268/20mg
    Ecliptasaponin A

    Catalog No: CFN93253
    CAS No: 78285-90-2
    Price: $100/20mg
    Cauloside A

    Catalog No: CFN96440
    CAS No: 17184-21-3
    Price: $318/10mg
    Hederagenin 3-O-(2-O-acetyl-alpha-L-arabinopyranoside)

    Catalog No: CFN95355
    CAS No: 87562-05-8
    Price: $318/10mg
    alpha-Hederin

    Catalog No: CFN98325
    CAS No: 27013-91-8
    Price: $60/20mg
    Glycoside L-F2

    Catalog No: CFN00446
    CAS No: 243857-99-0
    Price: Inquiry(manager@chemfaces.com)
    Carbohydr Res. 2017 Apr 10;442:9-16.
    Synthesis and cytotoxicity of oleanolic acid trisaccharide saponins.[Pubmed: 28273565]

    METHODS AND RESULTS:
    An array of oleanolic acid-type saponins based on β-hederin has been synthesized in a linear or one-pot manner. The cell viability assays indicate that synthetic saponins show antiproliferation activities in three cancer cell lines with IC50 values of 2.4-15.1 μM and Hederacolchiside A1 being the most potent. The results demonstrate that the type of terminal monosaccharides and linkage position have apparent effects on cytotoxicities and selectivities of these saponins against cancer cell lines tested.
    CONCLUSIONS:
    This study is helpful for future development of more potent anticancer leads.
    Cancer Chemother Pharmacol. 2004 Nov;54(5):432-40.
    Inhibition of HUVEC tubulogenesis by hederacolchiside-A1 is associated with plasma membrane cholesterol sequestration and activation of the Ha-Ras/MEK/ERK cascade.[Pubmed: 15490165]
    Neoangiogenesis is critical to cancer proliferation and metastasis and constitutes an attractive target for cancer therapy. It has previously been demonstrated that hederacolchiside-A1 (HCol-A1), a triterpenoid saponin from Hedera colchica Koch, has antimelanoma potential. The goal of this study was to evaluate, in vitro, if in addition to its tumoricidal effect on melanoma cells, HCol-A1 might affect endothelial cell network formation.
    METHODS AND RESULTS:
    We investigated whether HCol-A1 affects matrigel-induced tubulogenesis and inhibits the viability (WST-1 assay) of human umbilical vein endothelial cells (HUVECs). To provide structure-activity relationships (SAR), studies were conducted on HCol-A1, oleanolic acid and hederacolchiside A (HCol-A), a triterpenoid saponin which possess the same sugar sequence as Hcol-A1. Plasma membrane cholesterol sequestration was studied by labelling with [3H]cholesterol and assayed with HCol-A1-cholesterol complexes. HCol-A1 signalling was investigated using immunoassays. In contrast to HCol-A and oleanolic acid, HCol-A1 inhibited matrigel-induced angiogenesis at micromolar concentration. Plasma membrane cholesterol sequestration was found to be critical for this activity. Activation of the Ras/MEK/ERK cascade appears to be one of the mechanisms by which Hcol-A1 affects HUVEC network formation. The predominant activation of the Ha-Ras isoform, which decreases HUVEC-tolerance to apoptosis, might contribute to the high susceptibility of this cell line to HCol-A1.
    CONCLUSIONS:
    Since cholesterol sequestration affects cell confluence-dependent remodelling of endothelial membranes and vascular endothelial growth factor receptor-2 activity, these results raise the possibility that Hcol-A1 might slow-down cancer proliferation and metastasis in vivo by inhibiting critical aspects of neoangiogenesis. Further in vivo studies are needed to verify this hypothesis.
    Planta Med. 2000 May;66(4):343-7.
    Antileishmanial activity of three saponins isolated from ivy, alpha-hederin, beta-hederin and hederacolchiside A1, as compared to their action on mammalian cells cultured in vitro.[Pubmed: 10865451]
    The in vitro antileishmanial activity of three saponins isolated from ivy, alpha-hederin, beta-hederin and Hederacolchiside A1, was investigated on Leishmania infantum.
    METHODS AND RESULTS:
    The assessment of possible targets (membrane integrity, membrane potential, DNA synthesis and protein content) was performed in both Leishmania promastigotes and human monocytes (THP1 cells). Results observed in Leishmania showed that the saponins exhibited a strong antiproliferative activity on all stages of development of the parasite by altering membrane integrity and potential: Hederacolchiside A1 appeared to be the most active compound against both promastigotes and amastigotes. Results observed in THP1 cells demonstrated that the saponins exerted also a potent antiproliferative activity against human monocytes, by producing a significant DNA synthesis inhibition.
    CONCLUSIONS:
    The ratio between antileishmanial activity on amastigotes and toxicity to human cells suggested that the saponins could be considered as possible antileishmanial drugs.
    Melanoma Res. 2004 Apr;14(2):97-105.
    In addition to membrane injury, an affinity for melanin might be involved in the high sensitivity of human melanoma cells to hederacolchiside A1.[Pubmed: 15057038]
    We previously reported that Hederacolchiside A1 (Hcol A1), a new oleanene saponin isolated from Hedera colchica Koch (Araliaceae) exhibits a preferential cytotoxicity on a pigmented melanoma cell line.
    METHODS AND RESULTS:
    The present study confirms the high susceptibility of melanoma cell lines to this drug and shows concentrations producing a 50% decrease in cell content (IC50 values) inversely proportional to the melanin content of each cell line. At cytotoxic concentrations, Hcol A1 induces membrane-damaging effects within 6 h, cytoplasmic vacuolization within 24 h, and non-apoptotic cell death within 48 h. Using a new high-resolution magic-angle spinning nuclear magnetic resonance method, we have shown for the first time that this hederasaponin specifically interacts with melanin. The dissociation constant (2.7 mM) is comparable to those observed with drugs known to interact with melanin.
    CONCLUSIONS:
    Taking into consideration that the IC50 values were inversely proportional to the melanin in each cell line, our data suggest that, in addition to the delayed membrane injury induced by this drug, the ability of Hcol A1 to bind melanin could contribute to the higher toxicity of Hcol A1 in pigmented melanoma cells.
    Buddlenoid A

    Catalog No: CFN95025
    CAS No: 142750-32-1
    Price: $368/5mg
    1-O-galloyl-6-O-cinnamoylglucose

    Catalog No: CFN95053
    CAS No: 115746-69-5
    Price: $338/5mg
    Clemastanin B

    Catalog No: CFN95064
    CAS No: 112747-98-5
    Price: $368/20mg
    Momordicine II

    Catalog No: CFN95167
    CAS No: 91590-75-9
    Price: $318/10mg
    Lappaol B

    Catalog No: CFN95242
    CAS No: 62359-60-8
    Price: $333/10mg
    Quasipanaxatriol

    Catalog No: CFN95248
    CAS No: 171903-78-9
    Price: $413/5mg
    New compound 5

    Catalog No: CFN95258
    CAS No: N/A
    Price: $413/5mg
    alpha-Costic acid

    Catalog No: CFN95322
    CAS No: 28399-17-9
    Price: $318/5mg
    Acacetin 7-[rhamnosyl-(1->2)-galacturonide]

    Catalog No: CFN95358
    CAS No: 38722-95-1
    Price: $318/10mg
    Sativanone

    Catalog No: CFN95388
    CAS No: 70561-31-8
    Price: $318/10mg